Sources
No specific external URLs were cited in this article. Analysis reflects the author’s interpretation of publicly available cannabis industry data, company financial filings, regulatory announcements, and market information current as of February 27, 2026. Individual data access dates were not recorded.
Curaleaf’s recent \$500 million three-year loan at 11.5% interest reveals a troubling truth: the market is pricing in real default risk for the cannabis industry’s largest MSO. While the capital provides short-term liquidity, the cost signals deeper concerns about long-term viability and profitability timelines.